EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice

Ippei Fukada iD, Seiichi Mori, Naomi Hayashi, Mari Hosonaga, Wang Xiaofei, Masumi Yamazaki, Arisa Ueki, Kazuma Kiyotani iD, Akiko Tonooka, Kengo Takeuchi, Takayuki Ueno iD, Shunji Takahashi

Cancer Science · 2023-12 · 114 (12) · 4632-4642

DOI: 10.1111/cas.15993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 19.10.2023. Verfasst von Ippei Fukada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer genomic profile (CGP) testing, which is covered by the national health insurance system in Japan, has been introduced as a routine clinical practice. However, the effects of CGP testing on prognoses remain unclear. Drug accessibility rates and prognoses after CGP testing were retrospectively investigated in 713 patients who underwent CGP testing examined by our molecular tumor board between November 2019 and October 2022,. Overall survival (OS) was examined using the log‐rank test and the Kaplan–Meier method. The median age of patients (326 males and 387 females) was 58 years (12–85 years). CGP testing revealed one or more gene mutations in 681 cases (95.5%), among which actionable gene mutations were detected in 439 (61.6%). Although treatment options were recommended for 285 cases (40.0%) by the molecular tumor board, only 45 received treatment based on their gene mutations. During the median observation period of 8.6 months, 351 (49.2%) patients died of the exacerbation of existing diseases. No significant differences were observed in OS between patients treated with and without genomically matched therapy ( p = 0.285). According to clinical responses to treatment based on gene mutations, median OS was significantly longer in patients who achieved partial response and stable disease (26.5 months; 95% CI 14.4–38.6) than in those with progressive disease and not evaluated (9.8 months; 95% CI 5.8–13.8, p = 0.013). Responses to treatment based on gene mutations may improve prognoses, and it is important to increase the drug accessibility rate after CGP testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsNeoplasms, Second PrimaryMaleFemaleHumansMiddle AgedPrognosisRetrospective StudiesMutationGenomics

Stichwörter der Autor:innen

advanced solid tumorcancer genomic profile testclinical responsegenomically matched therapyprecision cancer medicine

Autor:innen und Institutionen

  • Genomic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Division of Cancer Genomics, Japanese Foundation for Cancer Research, Cancer Institute, Tokyo, Japan.
  • Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • The Advanced Medical Development, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Clinical Genetic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

ORCID-Profile: Ippei Fukada, Kazuma Kiyotani, Takayuki Ueno

Zitieren

APA

Fukada, I., Mori, S., Hayashi, N., Hosonaga, M., Xiaofei, W., Yamazaki, M., Ueki, A., Kiyotani, K., Tonooka, A., Takeuchi, K., Ueno, T., & Takahashi, S. (2023). Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice. Cancer Science, 114(12), 4632-4642. https://doi.org/10.1111/cas.15993

Vancouver

Fukada I, Mori S, Hayashi N, Hosonaga M, Xiaofei W, Yamazaki M, et al. Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice. Cancer Science. 2023;114(12):4632-4642. doi:10.1111/cas.15993

BibTeX
@article{Fukada2023,
  author = {Fukada, Ippei and Mori, Seiichi and Hayashi, Naomi and Hosonaga, Mari and Xiaofei, Wang and Yamazaki, Masumi and Ueki, Arisa and Kiyotani, Kazuma and Tonooka, Akiko and Takeuchi, Kengo and Ueno, Takayuki and Takahashi, Shunji},
  title = {Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice},
  journal = {Cancer Science},
  year = {2023},
  volume = {114},
  number = {12},
  pages = {4632--4642},
  doi = {10.1111/cas.15993}
}
Kostenlos starten →